1 day ago
1
georgeclerk
Truist Securities launched its coverage of Teva Pharmaceutical (NYSE:TEVA) with a Buy recommendation on Wednesday, citing its long-term growth strategy as the generic drugmaker prepares to host its Innovation & Strategy Day on May 29.
Analyst Les Sulewski issued a $25
English (US) ·